Silence Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs
Silence Therapeutics plc (Nasdaq: SLN) said it closed an underwritten public offering of 14,907,407 American Depositary Shares at $13.50 per ADS, including full exercise of the underwriters’ option for 1,944,444 additional ADSs. Gross proceeds were about $201.3 million before fees. Joint book-runners were Jefferies, Morgan Stanley, Cantor and William Blair.
How this was made
The 30-second read
Why it matters
Closing the upsized ADS offering at a fixed price creates an immediate supply overhang risk, but also provides ~$201.3 million gross proceeds to fund operations and pipeline development.
Market read
This is a completed capital raise with disclosed final size and price, which can drive short-term trading around dilution and funding expectations.
What to watch
Net proceeds and planned use of funds are not provided here, so traders should check the final prospectus for runway, dilution math, and any covenants or overhang timing.
Background
Silence Therapeutics is a clinical-stage biotech developing siRNA therapies and filed a shelf registration statement that became effective in late May 2026.
Ticker impact
Silence Therapeutics closed an upsized public offering of 14,907,407 ADSs at $13.50, including full underwriter option for 1,944,444 more ADSs.
Likely near-term negative-to-neutral bias from dilution expectations, with stabilization if investors focus on balance-sheet runway.
The article discloses the final offering size and price but not net proceeds use or immediate guidance; offering closings often weigh on valuation absent offsetting fundamentals.
Market effects
Adds to the biotech financing tape, reinforcing that clinical-stage siRNA developers are actively raising capital via ADS offerings.
Primarily US-listed biotech sentiment, with London-based issuer branding.
Limited beyond the small-cap biotech funding channel.
Counterpoint
The market may over-discount dilution if the proceeds materially extend cash runway into key clinical milestones.
Key entities
- issuerSilence Therapeutics plc
Nasdaq-listed clinical-stage biotech that closed an upsized underwritten ADS offering.
- securityAmerican Depositary Shares (ADSs)
Each ADS represents three ordinary shares; offering price was $13.50 per ADS.
- transaction_partiesUnderwriters (Jefferies, Morgan Stanley, Cantor, William Blair)
Joint book-running managers; exercised option to purchase additional ADSs in full.
